1-palmitoyl-lysophosphatidic acid (PLPA)

RN given refers to parent cpd without isomeric designation

Also Known As:

PLPA; 1-palmitoyl-lysophosphatidic acid, (R)-isomer; 1-palmitoyl-lysophosphatidic acid, sodium salt, (R)-isomer; 1-palmitoyl-rac-glycerol 3-phosphate; 1-palmitoyl-sn-glycerol 3-phosphate; Hexadecanoic acid, 2-hydroxy-3-(phosphonooxy)propyl ester

Networked: 10 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Lipids: 114793
- Membrane Lipids: 1591
  - Phospholipids: 11903
    - Glycerophosphates: 118
      - Phosphatidic Acids: 358
        Lysophospholipids: 554
        1-palmitoyl-lysophosphatidic acid: 10

Experts

1.	Xiang, Jim: 3 articles (11/2015 - 02/2002)
2.	Kim, Byoung Sik: 2 articles (02/2022 - 10/2017)
3.	Kim, Myung Hee: 2 articles (02/2022 - 10/2017)
4.	Chen, Zhuang: 2 articles (08/2003 - 02/2002)
5.	Liu, Yongqing: 2 articles (08/2003 - 02/2002)
6.	Zhang, Weidong: 2 articles (12/2002 - 02/2002)
7.	Cho, Changyi: 1 article (02/2022)
8.	Choi, Sanghyeon: 1 article (02/2022)
9.	Fox, Stephen: 1 article (05/2019)
10.	Kotelba, Adrian: 1 article (05/2019)

Related Diseases

1.	Neoplasms (Cancer) 11/01/2015 - "We generated CD40L-expressing (EG7-CD40L) and the control (EG7-Null) EG7 tumor cells by transfection of EG7 tumor cells with CD40L-expressing adenoviral vector AdVCD40L and the control vector AdV(pLpA), respectively. " 08/01/2003 - "Vaccinations of Mut1-pulsed DCs, DC(pLpA) and DC(Flt3L) all protected mice from challenge of low dose (0.5 x 10(5)) tumor cells. " 02/01/1999 - "In mice bearing large tumors, this treatment also caused significant inhibition of tumor growth with a mean tumor weight of 0.65 g vis-a-vis 3.05 g for tumors injected with the control AdV-pLpA. " 02/01/2002 - "Vaccination of mice with Mut1 peptide-pulsed control virus-transfected DC (DC(pLpA)) could only protect mice from challenge of a low dose (0.5 x 10(5) cells per mouse, 8/8 mice), but not a high dose (3 x 10(5) cells per mouse, 0/8 mice) of 3LL tumor cells. " 02/01/1999 - "In mice bearing small tumors, intratumoral injection of 2X10(9) pfu of AdV-TNF-alpha virus with a repeated booster treatment resulted in complete regression of three tumors and significant diminution of the other two with a mean tumor-weight of 0.16 g; this is in contrast to 0.85 and 1.62 g for tumors injected with the control AdV-pLpA and PBS respectively (p < 0.01). "
2.	Infections 10/13/2017 - "Compared with the wild type, the plpA mutant exhibited reduced mortality, systemic infection, and inflammation in mice as well as low cytotoxicity toward the human epithelial INT-407 cells. " 10/13/2017 - "We performed a transcriptome analysis on V. vulnificus after infection of human intestinal HT29-methotrexate cells and found induction of plpA, encoding a putative phospholipase, VvPlpA. " 11/01/1998 - "After the in vitro transfection of pLpA/M4-TNF-alpha at a multiplicity of infection of 1000, transfected VKCK cells showed significant secretion of RM4/TNF-alpha (36 ng/mL/10(6) cells) containing the functional TNF-alpha moiety in tissue culture. " 12/01/2002 - "MDCs infected with AdV-TNF-alpha and AdV-pLpA (no gene insert) at 100 multiplicity of infection (MOI) were analyzed by RNase protection assay for their cytokine secretion. "
3.	Inflammation (Inflammations) 10/13/2017 - "Compared with the wild type, the plpA mutant exhibited reduced mortality, systemic infection, and inflammation in mice as well as low cytotoxicity toward the human epithelial INT-407 cells. "
4.	Calculi (Calculus) 05/28/2019 - "In addition to PLPA and situated entropy, this framework encompasses Markov processes, the theory of perturbations, and calculus of variations. "
5.	Blister (Bulla) 02/01/2022 - "When a recombinant PlpA was treated on the blebbed cells, the blebs were completely disrupted. " 02/01/2022 - "Together, these findings indicate that the pore forming MARTX toxin and the phospholipase A2, PlpA, cooperate sequentially to achieve rapid necrotic cell death by inducing cell blebbing and disrupting the blebs, respectively."

Related Drugs and Biologics

1.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
2.	Phospholipases A2 (Phospholipase A2)
3.	Cytokines
4.	Staphylococcal Protein A (Protein A)
5.	Ribonucleases (Ribonuclease)
6.	Phospholipases (Phospholipase)
7.	Phosphates (Orthophosphate)
8.	Peptides (Polypeptides)
9.	Peroxidase (Myeloperoxidase)

Related Therapies and Procedures

1.	Injections